FDA approval of CARDAMYST represents first new option in 30 years for the more than two million patients with PSVTParticipants using CARDAMYST in ...
Silvaco Group surged over 50% post-Q4 FY25 earnings last week, driven by strong TCAD bookings and explosive SIP revenue ...
Ovid Therapeutics advances OV329, a GABA-AT inhibitor, into Phase 2 for drug-resistant adult focal onset seizures post soticlestat failure. See why OVID stock is a buy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results